Summary & Overview
HCPCS G9765: Documentation of Systemic Therapy Decline or Contraindication
HCPCS Level II code G9765 captures clinician documentation that a patient either declined a change in medication, alternative therapies were unavailable, there are documented contraindications, or the patient has not used a systemic medication for at least six consecutive months due to adverse effects or lack of efficacy. Nationally, this code matters because it supports clinical justification for ongoing management decisions in chronic dermatologic conditions and can affect coverage determinations for advanced therapies.
Key payers in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents, the clinical contexts in which it is used, and the service and site-of-service implications. The publication outlines typical benchmarks and policy-relevant considerations for documentation supporting systemic therapy decisions, highlights common payer considerations, and summarizes clinical measures referenced by the code (PGA, BSA, PASI, DLQI).
This summary is intended to inform billing, compliance, and clinical teams about the purpose and administrative role of G9765, and to clarify what documentation is signaled by the code for national payers and programs.
Billing Code Overview
HCPCS Level II code G9765 documents that a patient declined a change in medication or that alternative therapies were unavailable, has documented contraindications, or has not been treated with a systemic medication for at least six consecutive months (for example, experienced adverse effects or lack of efficacy with all other therapy options) in order to achieve better disease control as measured by PGA, BSA, PASI, or DLQI.
-
Service type: Documentation of treatment history and therapeutic rationale for chronic dermatologic disease management
-
Typical site of service: Outpatient dermatology clinics, specialty medical offices, infusion or biologic therapy centers where systemic therapy decisions and documentation occur
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 48-year-old patient with chronic moderate-to-severe plaque psoriasis attends a dermatology follow-up to determine candidacy for systemic biologic therapy. The patient has tried multiple topical therapies and phototherapy with inadequate control. Over the prior six months the patient either experienced significant adverse effects or lack of efficacy with several systemic agents, or the clinician documented contraindications (for example, active infection, pregnancy intent, or specific comorbidity) that preclude systemic treatment. Alternatively, the patient may have been offered medication changes or alternative systemic options and explicitly declined.
The clinical workflow includes: a focused history documenting prior therapies, adverse effects, and patient decision-making; objective severity measurement using PGA, BSA, PASI, or DLQI; review of laboratory and screening studies as appropriate; documentation of contraindications or patient refusal; and an explicit note stating the duration without systemic therapy (at least six consecutive months) or reasons for unavailability of alternatives. This documentation supports reporting of G9765 to indicate medical necessity rationale when systemic treatment is not currently used or cannot be initiated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural service | Use when documentation supports substantially greater work than typical for the visit or service related to complex medical decision-making and extensive coordination for therapy alternatives. |